Document Detail


Propafenone--a new agent for the treatment of ventricular arrhythmias.
MedLine Citation:
PMID:  2679087     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Over the last several years a number of new and potent antiarrhythmic agents have been developed. One of these promising new drugs, propafenone hydrochloride (Rhythmol), will soon be available for use in this country. Although similar in some aspects to flecainide and encainide, the drug possesses some unique characteristics. The purpose of this review is to summarize the pharmacologic and physiologic effects of propafenone and to outline its clinical use.
Authors:
B P Grubb
Related Documents :
3107447 - Life-threatening flecainide toxicity. a pharmacodynamic approach.
1328897 - Enantioselectivity of asocainol studied at different conditions: a novel approach to ch...
6185777 - Serial electrophysiologic effects of bretylium in man and their correlation with plasma...
15534787 - Preclinical strategies to assess qt liability and torsadogenic potential of new drugs: ...
2270697 - Pathophysiologic changes in the critically ill patient: risk factors for ulceration and...
20635737 - Antiplatelet drug resistance in patients with recurrent acute coronary syndrome undergo...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of the medical sciences     Volume:  298     ISSN:  0002-9629     ISO Abbreviation:  Am. J. Med. Sci.     Publication Date:  1989 Oct 
Date Detail:
Created Date:  1989-11-17     Completed Date:  1989-11-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370506     Medline TA:  Am J Med Sci     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  249-51     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, Medical College of Ohio, Toledo 43699.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arrhythmias, Cardiac / drug therapy*
Humans
Propafenone / adverse effects,  pharmacokinetics,  therapeutic use*
Ventricular Fibrillation / drug therapy
Chemical
Reg. No./Substance:
54063-53-5/Propafenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk factors in early life as predictors of adult heart disease: the Bogalusa Heart Study.
Next Document:  Autosomal recessive form of connatal Pelizaeus-Merzbacher disease.